Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Bachmann, Friederike ; Schreder, Martin

; Engelhardt, Monika ; Langer, Christian ; Wolleschak, Denise ; Mügge, Lars Olof ; Dürk, Heinz ; Schäfer-Eckart, Kerstin ; Blau, Igor Wolfgang ; Gramatzki, Martin ; Liebisch, Peter ; Grube, Matthias ; v Metzler, Ivana ; Bassermann, Florian ; Metzner, Bernd

; Röllig, Christoph ; Hertenstein, Bernd ; Khandanpour, Cyrus

; Dechow, Tobias ; Hebart, Holger ; Jung, Wolfram ; Theurich, Sebastian

; Maschmeyer, Georg ; Salwender, Hans ; Hess, Georg

; Bittrich, Max

; Rasche, Leo ; Brioli, Annamaria

; Eckardt, Kai-Uwe ; Straka, Christian ; Held, Swantje ; Einsele, Hermann

; Knop, Stefan

Alternative links to fulltext:DOI Publisher

Details

Indexed in

Export bibliographical data

Abstract

Abstract

Simple Summary Renal insufficiency is frequently seen in newly diagnosed multiple myeloma and can be due to the disease itself but also caused by medical interventions or infections. Patients with severe renal insufficiency are known to have an adverse prognosis, but recently, it was shown that even moderately impaired kidney function can have long-term sequelae. Achieving quick disease control by effective antimyeloma therapy can lead to the recovery of renal function. We investigated the kidney-specific variables in a large cohort of 770 myeloma patients receiving three different three-drug regimens for initial myeloma treatment to learn more about the differential effects on kidney function in an early disease phase. All regimens had a positive impact on kidney function without a difference in the proportion of patients who reached normal renal function after three cycles. Interestingly, patients who received bortezomib, lenalidomide, and dexamethasone tended to have higher risk for a worse renal function following induction when compared to the initial values. Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined "renal complete response (CRrenal)" was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment "renal fitness" in the latter group.

Owner only: item control page

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

Details

Indexed in

Export bibliographical data

Abstract

Abstract

Alternative Statistics (altmetrics)

More literature (via CORE)

University Library